Damage and Renal Clearance of Glycocalyx in Cardiac Surgery

Cardio-Renal Syndrome Clinical Trial

— GlycoCarSur  

Official title:

Damage and Renal Clearance of Glycocalyx in Cardiac Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04332952
• Other study ID #: Cardiologia-002
• Status: Completed
• Start date: August 1, 2017
• Est. completion date: December 31, 2017

Study information

• Verified date: April 2020
• Source: Hospital Beneficencia Espanola de Puebla
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The glycocalyx is a component of the vascular endothelium that currently plays a relevant role in the modified Starling theory.

The manipulation of the heart during cardiac surgery stimulates the release of the natriuretic atrial peptide, which causes endothelial wear in patients undergoing extracorporeal circulation. Dilation of the atrium produces natriuretic atrial peptide, which reduces plasma volume by increasing renal excretion and vascular permeability. The atrial peptide degrades the surface of the coronary endothelium, causing loss of the side cam protein nucleus. This study investigates the relationship between clamping time in cardiac surgery and the clearance of endothelial inflammation markers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: December 31, 2017
• Est. primary completion date: October 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Over 18 years of age

• Patients who underwent cardiac surgery for a single valve change or replacement

Exclusion Criteria:

• Stage 3 renal failure patients

• Patients with a previous diagnosis of hematological malignancy

• Patients undergoing pulmonary valve change surgery.

• Patients undergoing Bentall and Bono surgery.

• Patients Undergoing Coronary Artery Bypass Surgery

Related Conditions & MeSH terms

• Cardio-Renal Syndrome
• Glycocalyx

Locations

Country	Name	City	State
Mexico	Hospital Beneficencia Española de Puebla	Puebla

Sponsors (2)

Lead Sponsor	Collaborator
Miguel Ayala León	Instituto Nacional de Cardiologia Ignacio Chavez

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Extracorporeal circulation time	Duration of Extracorporeal Circulation in minutes	2 hours
Primary	Aortic clamping time	Duration of aortic clamping time in minutes	2 hours
Primary	Hyaluronic acid levels in blood before surgery	Quantity of hyaluronic acid in blood before surgery	30 minutes
Primary	Hyaluronic acid levels in blood after surgery	Quantity of hyaluronic acid in blood after surgery	30 minutes
Primary	Hyaluronic acid levels in urine before surgery	Quantity of hyaluronic acid in urine before surgery	30 minutes
Primary	Hyaluronic acid levels in urine after surgery	Quantity of hyaluronic acid in urine before surgery	30 minutes
Primary	Sydecan -1 levels in blood before surgery	Quantity of Sydecan -1 in blood before surgery	30 minutes
Primary	Sydecan -1 levels in blood after surgery	Quantity of Sydecan -1 in blood after surgery	30 minutes
Primary	Sydecan -1 levels in urine before surgery	Quantity of Sydecan -1 in urine before surgery	30 minutes
Primary	Sydecan -1 levels in urine after surgery	Quantity of Sydecan -1 in urine after surgery	30 minutes